Foghorn Therapeutics (FHTX) Cash & Current Investments (2019 - 2026)

Foghorn Therapeutics' Cash & Current Investments history runs 8 years deep, the most recent figure standing at $88.9 million for Q1 2026.

• In Q1 2026, Cash & Current Investments rose 45.7% year-over-year to $88.9 million; the TTM figure through Mar 2026 stood at $88.9 million (up 45.7% YoY), while the FY2025 annual figure was $82.1 million, up 48.1% from the prior year.
• Cash & Current Investments was $88.9 million for Q1 2026 at Foghorn Therapeutics, up from $82.1 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $213.6 million in Q1 2022 to a low of $50.6 million in Q1 2023.
• Historically, Cash & Current Investments has averaged $82.4 million across 5 years, with a median of $73.8 million in 2025.
• The sharpest annual moves came in 2022 and 2023: Cash & Current Investments soared 221.52% in 2022, then slumped 76.3% in 2023.
• A 5-year view of Cash & Current Investments shows it stood at $52.2 million in 2022, then surged by 53.86% to $80.3 million in 2023, then plunged by 30.97% to $55.5 million in 2024, then surged by 48.1% to $82.1 million in 2025, then climbed by 8.26% to $88.9 million in 2026.
• The last three Cash & Current Investments figures came in at $88.9 million (Q1 2026), $82.1 million (Q4 2025), and $90.6 million (Q3 2025), per Business Quant data.